There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
Transcript (slightly modified)
Are the results of trials evaluating the new checkpoint inhibitors in breast cancer encouraging?
There are trials evaluating the checkpoint inhibitors in breast cancer. We’re very excited about this group of agents, in general, which has shown benefit across a large variety of tumors. The data to date, in breast cancer, has been focused on metastatic disease and there are small populations, typically in phase 1 studies of the checkpoint inhibitors, the PD-1 inhibitors specifically, which have been reported.
The results show that there is some benefit in populations, particularly perhaps in the triple negative breast cancer population. The response rates seem a little bit lower than we see in some other diseases like lung cancer, and certainly lower than we see in a disease that’s very immune sensitive like melanoma. One of the hypotheses is that tumors that have large amount of genomic instability, lots of mutations like lung cancer, are more likely to respond to checkpoint inhibitors.
So part of the drive now in breast cancer is to define the subgroup of patients who might be most suited to checkpoint inhibitors. This is an area of very active discussion and investigation, and I think over the next year or 2 we’ll see much more about checkpoint inhibitors in metastatic breast cancer.
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen